Replies to post #75978 on NanoViricides Inc. (NNVC)

[Puffer]

that information is way out of date, is NOT in the latest 10K, and does NOT include mention of the very broad patent issued (PCT/US06/01820
(SOLUBILIZATION AND TARGETED DELIVERY OF DRUGS WITH SELF-ASSEMBLING AMPHIPHILIC POLYMERS) in May of last year.

We have previously announced certain important issuances of patents on the TheraCour® technology underlying our nanoviricides® drugs. Most importantly, a fundamental patent on the polymeric micelles composition, structure and uses was issued in the USA with substantially broad claims. This validates the novelty of our approach as well as our leadership position in the nanomedicines based on polymeric micelle technologies. All of the patent applications have been filed internationally. To date more than 20 patent grants have occurred and additional grants continue as the applications progress through review.

substantially broad claims.... doesn't sound so inferior does it?

Here is what was completely twisted by the author of that article --

Of the patents and technologies licensed, the Company believes that the Company will not be using the intellectual property, compositions of matter, or other aspects described and secured under the US Patent No. US 6,521,736. The Company believes that this patent describes an inferior technology compared to the technology in the later patent filings of Dr. Diwan. This patent, the Company believes, discloses prototype materials that served to establish the proof of principles developed by Dr. Anil Diwan, the Company’s President and co- founder, whether such materials were possible to create and whether such materials would indeed be capable of encapsulation of pharmaceutically relevant compounds. The Company believes that the new and novel compositions disclosed in the new patent applications, No. PCT/US06/01820, and No. PCT/US2007/001607, and additional proprietary intellectual property provide the necessary features that enable the development of nanoviricides. The Company believes that no other published literature materials or existing patents are capable of providing all of the necessary features for this development, to the best of our knowledge. However, the Company has no knowledge of the extensive active internal developments at a number of companies in the targeted therapeutics area.

No partnerships with Big Pharma yet because they are extremely risk averse and usually wait until proof of efficacy in humans. A successful Phase I/IIa and they will come flocking.

You guys seem to want nothing to do with anything that may be seen as adverse and attack it.

No, its just that all the unsubstantiated false claims gets tiring. Bring a valid point and we will be all over it. Too many times, it appears, the correction of outright falsehoods gets taken as not wanting to hear anything negative about the company. Complete nonsense.

[arch433]

If this was such a foregone conclusion like most think here then the stock would be at $100 by now. Of course there still exist inherent risks, to numerous to name. But, I do not subscribe to any of the conspiracy theories that have been floated around. I genuinely believe the Docs are doing he best they can and they honestly believe they have a technology for the future. If I did not believe this then I wouldn't be invested in NNVC.

You will always have your quacks on both sides of the fence. I will stick with my beliefs and the stock until proven otherwise. Until then I will drown out the noise and typical BS spewed on these boards and continue to root for their success!

[ZincFinger]

Partnering with BP at this point would be totally non nonsensical.

The earlier you partner on a drug, the lower the upfront money and the lower the royalties. Companies don't partner until

1) they need the money. NNVC does not, it has good cash reserves.

2) the company has taken the drug to a point beyond which it does not want to expend resources on it anymore and would rather focus on generating more drug candidates. THAT IS ALMOST ALWAYS PAST A "POINT OF INFLECTION": some critical data that greatly improves the prospects of the drug and means a partnership at that point would get a lot more money than just prior to it. None of NNVCs drugs are at that stage yet. A partnership would get much lower returns than one in even just a few months if things go well.

IMHO the only drug it would make sense for NNVC to partner before the first clinical trial would be HIV (because the CTs for it would be much longer and more expensive and the competition in the area is so high) but the current data is just way too early for a partnership on HIVcide.

With the other drugs, the clinical trials would be MUCH faster (due to very short conditions vs HIV is a life long conditon)due to qualifying for Orphan Drug, Breakthrough Drug, high probabilty of Early Approval (as early as in a Phase I/IIa) etc. NNVC could and should, IMHO take them all the way to approval before partnering (IF even then).

To put the rest in perspective, look up "boilerplate".

[FORZANANO]

I respect MalibuMan post.

I had a problem with the 1st paragraph of that website.

Read it and you will understand my point !

FN

[BonelessCat]

It's not that many of us don't want to hear negatives, it's that so often those pointing to negatives get it completely wrong, or have an agenda to trash the company by spinning something negative. For example, here is what the current 10K/a said about the base patent:

The Company also announced in May 2012 that a fundamental patent, on which the nanoviricides® technology is based, is due to be issued in the USA on May 8, 2012. The US Patent (No. 8,173,764) is granted for "Solubilization and Targeted Delivery of Drugs with Self-Assembling Amphiphilic Polymers." It was issued on May 8, 2012. The patent term is expected to last through October 1, 2028, including anticipated extensions in compensation for time spent in clinical trials. This US Patent has been allowed with a very broad range of claims to a large number of families of chemical structure compositions, pharmaceutical compositions, methods of making the same, and uses of the same. The disclosed structures enable self-assembling, biomimetic nanomedicines. NanoViricides, Inc. holds exclusive, perpetual, worldwide licenses to these technologies for a broad range of antiviral applications and diseases. The other national and regional counterparts of the international Patent Cooperation Treaty (“PCT”) application number PCT/US06/01820, which was filed in 2006, have issued as a Singapore National Patent Publication, a South African patent, and also as an OAPI regional patent covering Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Republic of Congo, Cote d'Ivoire, Equatorial Guinea, Gabon, Guinea, Guinea Bissau, Mali, Mauritania, Niger, Senegal, and Togo. It has also issued as a granted patent in New Zealand, China, Mexico, and Japan. Estimated expiry dates range nominally from 2026 to 2028 with various extensions accounting for delays in clinical trials. Additional issuances are expected in Europe, and in several other countries around the world.

Sorry if I don't see anywhere that says the patent won't be used. In fact, it states quite the opposite. Moreover, the original patent issued jointly to UMASS and Dr. Diwan was a version of the nanomicelle that has key structural differences from the nanomicelle now patented, protect and licensed to NNVC. It was designed as a Therapeutic Courier (from which TheraCour is derived) for transport and delivery of active pharmaceutical ingredients to targeted sites. That old patent is the one to which you may be referring.